Cityengine Pro 2010 Pcp

1. Cityengine Pro 2010 Pcpao

PCP File Summary

Cityengine Pro 2010 Pcpao

Tools.v2010.12.SP2.Linux Synopsys.Synplify.Premier.v2012.09.Win Synopsys.Synplify.FPGA.v2012.03.Win Synopsys.Syn(Design.Complier.).v2012.06.Linux. Bar Cut Optimizer Manager v1.21. BCAD Designer v3.8.539 BestColour.

There are five file types associated with the PCP File Extension, with the most widely-observed being the Windows Installer Patch Creation Properties File format. According to our database, seven distinct software programs (conventionally, Microsoft Windows SDK developed by Microsoft Corporation) will enable you to view these files. Generally, these files are considered Developer Files, but they can also be Game Files or Settings Files.

Windows, iOS, and Playstation 3 System Software operating systems can be used to view PCP files. Both desktop and mobile devices enable you to view and (sometimes) edit these files, depending on the software used. The PCP File Extension carries a Popularity Rating of 'Low', meaning that these files are scarcely found in most user's file stores.

If you would like to learn more about PCP files and the software that opens them, please see the additional detailed information below. Also, you can learn how to do some basic PCP file troubleshooting if you are having trouble opening these files.

File Rank

/ 11690

Open your files in %%os%% with FileViewPro File Viewer

Optional Offer for FileViewPro by Solvusoft EULA Privacy Policy Terms Uninstall

Phencyclidine (PCP), also known as angel dust among other names, is a drug used for its mind-altering effects.^[5] PCP may cause hallucinations, distorted perceptions of sounds, and violent behavior.^[7][8] As a recreational drug, it is typically smoked, but may be taken by mouth, snorted, or injected.^[7][4] It may also be mixed with cannabis or tobacco.^[5]

Adverse effects may include seizures, coma, addiction, and an increased risk of suicide.^[7]Flashbacks may occur despite stopping usage.^[8] Chemically, PCP is a member of the arylcyclohexylamineclass, and pharmacologically, it is a dissociative anesthetic.^[9][10] PCP works primarily as an NMDA receptor antagonist.^[9]

PCP is most commonly used in the United States.^[11] While usage peaked there in the 1970s,^[12] between 2005 and 2011 an increase in visits to emergency departments as a result of the drug occurred.^[7] As of 2017 in the United States about 1% of people in grade twelve reported using PCP in the prior year while 2.9% of those over the age of 25 reported using it at some point in their life.^[13]

PCP was initially made in 1926 and brought to market as an anesthetic medication in the 1950s.^[10][14] Its use in humans was disallowed in the United States in 1965 due to the high rates of side effects while its use in other animals was disallowed in 1978.^[5][15][10] Moreover, ketamine was discovered and was better tolerated as an anesthetic.^[15] PCP is classified as a schedule II drug in the United States.^[5] A number of derivatives of PCP have been sold for recreational and non-medical use.^[16]

• 1Recreational uses
• 3Pharmacology
  • 3.2Mechanism of action
• 4Chemistry

Recreational uses[edit]

Phencyclidine is used for its ability to induce a dissociative state. ^[17]

Effects[edit]

Behavioral effects can vary by dosage. Low doses produce a numbness in the extremities and intoxication, characterized by staggering, unsteady gait, slurred speech, bloodshot eyes, and loss of balance. Moderate doses (5–10 mg intranasal, or 0.01–0.02 mg/kg intramuscular or intravenous) will produce analgesia and anesthesia. High doses may lead to convulsions.^[18] The drug is often illegally produced under poorly controlled conditions; this means that users may be unaware of the actual dose they are taking.^[19]

Psychological effects include severe changes in body image, loss of ego boundaries, paranoia, and depersonalization. Psychosis, agitation and dysphoria, hallucinations, blurred vision, euphoria, and suicidal impulses are also reported, as well as occasional aggressive behavior.^{[20][21]:48–49[18]} Like many other drugs, PCP has been known to alter mood states in an unpredictable fashion, causing some individuals to become detached, and others to become animated. PCP may induce feelings of strength, power, and invulnerability as well as a numbing effect on the mind.^[4]

Studies by the Drug Abuse Warning Network in the 1970s show that media reports of PCP-induced violence are greatly exaggerated and that incidents of violence are unusual and often limited to individuals with reputations for aggression regardless of drug use.^[21]:48 Although uncommon, events of PCP-intoxicated individuals acting in an unpredictable fashion, possibly driven by their delusions or hallucinations, have been publicized.^{[citation needed]} One example is the case of Big Lurch, a former rapper with a history of violent crime, who was convicted of murdering and cannibalizing his roommate while under the influence of PCP.^[22] Other commonly cited types of incidents include inflicting property damage and self-mutilation of various types, such as pulling one's own teeth.^[21]:48[22] These effects were not noted in its medicinal use in the 1950s and 1960s however, and reports of physical violence on PCP have often been shown to be unfounded.^[23][24]

Recreational doses of the drug also occasionally appear to induce a psychotic state that resembles a schizophrenic episode.^[25] Users generally report feeling detached from reality.^[26]

Symptoms are summarized by the mnemonic device RED DANES: rage, erythema (redness of skin), dilated pupils, delusions, amnesia, nystagmus (oscillation of the eyeball when moving laterally), excitation, and skin dryness.^[27]

Addiction[edit]

PCP is self-administered and induces ΔFosB expression in the D1-typemedium spiny neurons of the nucleus accumbens,^[1][28] and accordingly, excessive PCP use is known to cause addiction.^[1] PCP's rewarding and reinforcing effects are at least partly mediated by blocking the NMDA receptors in the glutamatergic inputs to D1-type medium spiny neurons in the nucleus accumbens.^[1] PCP has been shown to produce conditioned place aversion and conditioned place preference in animal studies.^[29]

Methods of administration[edit]

PCP comes in both powder and liquid forms (PCP base is dissolved most often in ether), but typically it is sprayed onto leafy material such as cannabis, mint, oregano, tobacco, parsley, or ginger leaves, then smoked.^{[citation needed]}

• PCP can be ingested through smoking. 'Fry' or 'sherm' are street terms for marijuana or tobacco cigarettes that are dipped in PCP and then dried.^[30]
• PCP hydrochloride can be insufflated (snorted), depending upon the purity.
• The free base is quite hydrophobic and may be absorbed through skin and mucus membranes (often inadvertently).

Management of intoxication[edit]

Management of PCP intoxication mostly consists of supportive care – controlling breathing, circulation, and body temperature – and, in the early stages, treating psychiatric symptoms.^[31][32][33]Benzodiazepines, such as lorazepam, are the drugs of choice to control agitation and seizures (when present). Typical antipsychotics such as phenothiazines and haloperidol have been used to control psychotic symptoms, but may produce many undesirable side effects – such as dystonia – and their use is therefore no longer preferred; phenothiazines are particularly risky, as they may lower the seizure threshold, worsen hyperthermia, and boost the anticholinergic effects of PCP.^[31][32] If an antipsychotic is given, intramuscular haloperidol has been recommended.^[33][34][35]

Forced acid diuresis (with ammonium chloride or, more safely, ascorbic acid) may increase clearance of PCP from the body, and was somewhat controversially recommended in the past as a decontamination measure.^[31][32][33] However, it is now known that only around 10% of a dose of PCP is removed by the kidneys, which would make increased urinary clearance of little consequence; furthermore, urinary acidification is dangerous, as it may induce acidosis and worsen rhabdomyolysis (muscle breakdown), which is not an unusual manifestation of PCP toxicity.^[31][32]

Pharmacology[edit]

Pharmacodynamics[edit]

PCP is well known for its primary action on the NMDA receptor, an ionotropic glutamate receptor, in rats and in rat brain homogenate.^[46][43] As such, PCP is an NMDA receptor antagonist. The role of NMDAR antagonism in the effect of PCP, ketamine, and related dissociative agents was first published in the early 1980s by David Lodge^[47] and colleagues.^[16] Other NMDA receptor antagonists include ketamine,^[48]tiletamine,^[49]dextromethorphan,^[50]nitrous oxide, and dizocilpine (MK-801).

Research also indicates that PCP inhibits nicotinic acetylcholine receptors (nAChRs) among other mechanisms. Analogues of PCP exhibit varying potency at nACh receptors^[51] and NMDA receptors.^[52] Findings demonstrate that presynaptic nAChRs and NMDA receptor interactions influence postsynaptic maturation of glutamatergic synapses and consequently impact synaptic development and plasticity in the brain.^[53] These effects can lead to inhibition of excitatory glutamate activity in certain brain regions such as the hippocampus^[54] and cerebellum^[55] thus potentially leading to memory loss as one of the effects of prolonged use. Acute effects on the cerebellum manifest as changes in blood pressure, breathing rate, pulse rate, and loss of muscular coordination during intoxication.^[8]

PCP, like ketamine, also acts as a potent dopamineD₂^High receptorpartial agonist in rat brain homogenate^[43] and has affinity for the human cloned D₂^High receptor.^[56] This activity may be associated with some of the other more psychotic features of PCP intoxication, which is evidenced by the successful use of D₂ receptor antagonists (such as haloperidol) in the treatment of PCP psychosis.^[57]

In addition to its well explored interactions with NMDA receptors, PCP has also been shown to inhibit dopamine reuptake, and thereby leads to increased extracellular levels of dopamine and hence increased dopaminergicneurotransmission.^[58] However, PCP has little affinity for the human monoamine transporters, including the dopamine transporter (DAT).^[38] Instead, its inhibition of monoamine reuptake may be mediated by interactions with allosteric sites on the monoamine transporters.^[38] PCP is notably a high-affinity ligand of the PCP site 2 (K_i = 154 nM), a not-well-characterized site associated with monoamine reuptake inhibition.^[39]

Studies on rats indicate that PCP interacts indirectly with opioid receptors (endorphin and enkephalin) to produce analgesia.^[59]

A binding study assessed PCP at 56 sites including neurotransmitter receptors and transporters and found that PCP had K_i values of >10,000 nM at all sites except the dizocilpine (MK-801) site of the NMDA receptor (K_i = 59 nM), the σ₂ receptor (PC12) (K_i = 136 nM), and the serotonin transporter (K_i = 2,234 nM).^[38] The study notably found K_i values of >10,000 nM for the D₂ receptor, the opioid receptors, the σ₁ receptor, and the dopamine and norepinephrine transporters.^[38] These results suggest that PCP is a highly selective ligand of the NMDAR and σ₂ receptor.^[38] However, PCP may also interact with allosteric sites on the monoamine transporters to produce inhibition of monoamine reuptake.^[38]

Mechanism of action[edit]

Phencyclidine is an NMDA receptor antagonist that blocks the activity of the NMDA receptor to cause anaesthesia and analgesia without causing cardiorespiratory depression.^[60][61] NMDA is an excitatory receptor in the brain, when activated normally the receptor acts as an ion channel and there is an influx of positive ions through the channel to cause nerve cell depolarisation. Phencyclidine enters the ion channel and binds, reversibly and non-competitively, inside the channel pore to block the entry of positive ions to the cell therefore inhibiting cell depolarisation.^[60][62]

Free download paradise bay game. It is no secret that King has entered a unique partnership with Microsoft. In the last few months, we have seen Candy Crush Saga, Soda Soga, Jelly Saga and Papa Pear Saga arrive as universal apps for Windows 10.Today, we can add one more to that roster with the release of Paradise Bay for Windows 10 and Mobile.

Neurotoxicity[edit]

Some studies found that, like other NMDA receptor antagonists, PCP can cause a kind of brain damage called Olney's lesions in rats.^[63][64] Studies conducted on rats showed that high doses of the NMDA receptor antagonist dizocilpine caused reversible vacuoles to form in certain regions of the rats' brains. All studies of Olney's lesions have only been performed on non-human animals and may not apply to humans. One unpublished study by Frank Sharp reportedly showed no damage by the NDMA antagonist, ketamine, a similar drug, far beyond recreational doses,^[65] but due to the study never having been published, its validity is controversial.

PCP has also been shown to cause schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate levels in the rat brain, which are detectable both in living rats and upon necropsy examination of brain tissue.^[66] It also induces symptoms in humans that mimic schizophrenia.^[67] PCP not only produced symptoms similar to schizophrenia, it also yielded electroencephalogram changes in the thalamocortical pathway (increased delta decreased alpha) and in the hippocampus (increase theta bursts) that were similar to those in schizophrenia.^[68] PCP induced augmentation of dopamine release may link the NMDA and DA hypothesis of schizophrenia.^[69]

Pharmacokinetics[edit]

PCP is metabolized into PCHP, PPC and PCAA. 90% of phencycledine is metabolised by oxidative hydroxylation in the liver on first pass. Metabolites are glucroniated and excreted in the urine. 9% of the drug is excreted in its unchanged form.^[61]

When smoked, some of the compound is broken down by heat into 1-phenylcyclohexene (PC) and piperidine.

It takes 15 to 60 minutes for effects of phencyclidine to come into action.^[61]

Chemistry[edit]

PCP is an arylcyclohexylamine.

Analogues[edit]

Fewer than 30 different analogs of PCP were reported as being used on the street during the 1970s and 1980s, mainly in the United States.^[16] Only of a few of these compounds were widely used including rolicyclidine (PCPy), eticyclidine (PCE), and tenocyclidine (TCP).^[16] Less common analogs include 3-HO-PCP, 3-MeO-PCMo, and 3-MeO-PCP.

The generalized structural motif required for PCP-like activity is derived from structure-activity relationship studies of PCP derivatives. All of these derivatives are likely to share some of their psychoactive effects with PCP itself, although a range of potencies and varying mixtures of anesthetic, dissociative, and stimulant effects are known, depending on the particular drug and its substituents. In some countries such as the United States, Australia, and New Zealand, all of these compounds would be considered controlled substance analogs of PCP under the Federal Analog Act and are hence illegal drugs if sold for human consumption.^[70][71]

Frequency of use[edit]

PCP began to emerge as a recreational drug in major cities in the United States in 1960s.^[7] In 1978, People magazine and Mike Wallace of 60 Minutes called PCP the country's 'number one' drug problem. Although recreational use of the drug had always been relatively low, it began declining significantly in the 1980s. In surveys, the number of high school students admitting to trying PCP at least once fell from 13% in 1979 to less than 3% in 1990.^[21]:46–49

History[edit]

It is commonly mistakenly reported that PCP was first synthesized in 1926.^[72] This early synthesis, in fact, refers to the PCP intermediate PCC.^[16] PCP was actually discovered by Victor Maddox, a chemist at Parke-Davis in Michigan, while investigating synthetic analgesic agents. Although unexpected, PCP was identified as potentially interesting, and as such, was submitted for pharmacological testing. The promising results of these pharmacological investigations led to the rapid development of PCP. It was approved for use as an investigational drug under the brand names Sernyl and Sernylan in the 1950s as an anesthetic, but because of its long terminal half-life and adverse side effects, such as hallucinations, mania, delirium, and disorientation, it was removed from the market in 1965 and limited to veterinary use.^[16][73][74]

Regulation[edit]

PCP is a Schedule II substance in the United States and its ACSCN is 7471.^[75] Its manufacturing quota for 2014 was 19 grams.^[76]

It is a Schedule I drug by the Controlled Drugs and Substances act in Canada, a List I drug of the Opium Law in the Netherlands, and a Class A substance in the United Kingdom.^[77]

References[edit]

1. ^ ^abcdMalenka RC, Nestler EJ, Hyman SE (2009). 'Chapter 15: Reinforcement and Addictive Disorders'. In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 374–375. ISBN9780071481274.
2. ^Stobo, John D.; Traill, Thomas A.; Hellmann, David B.; Ladenson, Paul W.; Petty, Brent G. (1996). The Principles and Practice of Medicine. McGraw Hill Professional. p. 933. ISBN9780071383653. high abuse liability
3. ^Fetting, Margaret (2015). Perspectives on Substance Use, Disorders, and Addiction: With Clinical Cases. SAGE Publications. p. 145. ISBN9781483377773.
4. ^ ^abc'NIDA InfoFacts: Hallucinogens – LSD, Peyote, Psilocybin, and PCP'. National Institute on Drug Abuse. Retrieved 2018-02-19.
5. ^ ^abcde'PCP Fast Facts'. National Drug Intelligence Center. 2003. Retrieved 19 February 2018.
6. ^ ^abRiviello, Ralph J. (2010). Manual of forensic emergency medicine : a guide for clinicians. Sudbury, Mass.: Jones and Bartlett Publishers. pp. 41–42. ISBN9780763744625.
7. ^ ^abcdeBush, DM (2013). 'Emergency Department Visits Involving Phencyclidine (PCP)'. PMID27656747.
8. ^ ^abc'Hallucinogens'. National Institute on Drug Abuse. January 2016. Retrieved 20 February 2018.
9. ^ ^abMarion, Nancy E.; Oliver, Willard M. (2014). Drugs in American Society: An Encyclopedia of History, Politics, Culture, and the Law [3 volumes]. ABC-CLIO. p. 732. ISBN9781610695961.
10. ^ ^abcZedeck, Beth E.; Zedeck, Morris S. (2007). Forensic Pharmacology. Infobase Publishing. p. 97. ISBN9781438103822.
11. ^'GINAD'. www.ginad.org.
12. ^'PCP'. CESAR. Retrieved 20 February 2018.
13. ^'Hallucinogens'. NIAD. Retrieved 20 February 2018.
14. ^Bunney, W. E. Jr; Hippius, Hanns; Laakmann, Gregor; Schmauß, Max (2012). Neuropsychopharmacology: Proceedings of the XVIth C.I.N.P. Congress, Munich, August, 15-19, 1988. Springer Science & Business Media. p. 717. ISBN9783642740343.
15. ^ ^abTasman, Allan; Kay, Jerald; Lieberman, Jeffrey A.; First, Michael B.; Riba, Michelle (2015). Psychiatry, 2 Volume Set. John Wiley & Sons. p. 4943. ISBN9781118753361.
16. ^ ^abcdefMorris H, Wallach J (2014). 'From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs'. Drug Testing and Analysis. 6 (7–8): 614–32. doi:10.1002/dta.1620. PMID24678061.
17. ^Millan, M. J.; Brocco, M.; Gobert, A.; Joly, F.; Bervoets, K.; Rivet, J. -M.; Newman-Tancredi, A.; Audinot, V.; Maurel, S. (December 1999). 'Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT sites for PCP-induced locomotion in the rat'. European Journal of Neuroscience. 11 (12): 4419–4432. doi:10.1046/j.1460-9568.1999.00858.x.
18. ^ ^abDiaz, Jaime. How Drugs Influence Behavior. Englewood Cliffs: Prentice Hall, 1996.
19. ^Chudler, Eric H. 'Neuroscience for Kids – PCP'. Neuroscience for Kids. Retrieved 2011-01-26.
20. ^Bey, T; Patel, A (February 2007). 'Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug'. The California Journal of Emergency Medicine. 8 (1): 9–14. PMC2859735. PMID20440387.
21. ^ ^abcdInciardi, James A. (1992). The War on Drugs II. Mayfield Publishing Company. ISBN978-1-55934-016-8.
22. ^ ^abDoes PCP turn people into cannibals? The Straight Dope, 2005
23. ^Brecher M, Wang BW, Wong H, Morgan JP (Dec 1988). 'Phencyclidine and violence: clinical and legal issues'. Journal of Clinical Psychopharmacology. 8 (6): 397–401. doi:10.1097/00004714-198812000-00003. PMID3069880.
24. ^Wish ED (1986). 'PCP and crime: just another illicit drug?'. NIDA Research Monograph. 64: 174–89. PMID3086733.
25. ^Luisada, PV (1978). Petersen, RC; Stillman, RC (eds.). 'The phencyclidine psychosis: phenomenology and treatment'(PDF). Phencyclidine (PCP) Abuse: An Appraisal. Rockville, Maryland: National Institute on Drug Abuse.
26. ^Pender JW (Oct 1972). 'Dissociative anesthesia'. California Medicine. 117 (4): 46–7. PMC1518731. PMID18730832.
27. ^Giannini, A. James (1997). Drugs of Abuse (Second ed.). Los Angeles: Practice Management Information Corp. p. 126. ISBN978-1-57066-053-5.
28. ^Nestler, EJ (October 12, 2008). 'Review. Transcriptional mechanisms of addiction: role of DeltaFosB'. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363 (1507): 3245–3255. doi:10.1098/rstb.2008.0067. PMC2607320. PMID18640924.Nestler EJ (October 2008). 'Table 1: Drugs of abuse known to induce ΔFosB in nucleus accumbens after chronic administration'. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363 (1507): 3245–55. doi:10.1098/rstb.2008.0067. PMC2607320. PMID18640924.
29. ^Noda, Y.; Nabeshima, T. (1 September 1998). 'Neuronal mechanisms of phencyclidine-induced place aversion and preference in the conditioned place preference task'. Methods and Findings in Experimental and Clinical Pharmacology. 20 (7): 607–611. doi:10.1358/mf.1998.20.7.485726. ISSN0379-0355. PMID9819806.
30. ^'Fry Fast Facts'. National Drug Intelligence Center.
31. ^ ^abcdHelman RS, Habal R (October 6, 2008). 'Phencyclidine Toxicity'. eMedicine. Retrieved on November 3, 2008.
32. ^ ^abcdOlmedo R (2002). 'Chapter 69: Phencyclidine and ketamine'. In Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS (eds.). Goldfrank's Toxicologic Emergencies. New York: McGraw-Hill. pp. 1034–1041. ISBN978-0-07-136001-2.
33. ^ ^abcMilhorn HT (Apr 1991). 'Diagnosis and management of phencyclidine intoxication'. American Family Physician. 43 (4): 1293–302. PMID2008817.
34. ^Giannini AJ, Price WA (1985). 'PCP: Management of acute intoxication'. Medical Times. 113 (9): 43–49.
35. ^Giannini AJ, Eighan MS, Loiselle RH, Giannini MC (Apr 1984). 'Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis'. Journal of Clinical Pharmacology. 24 (4): 202–4. doi:10.1002/j.1552-4604.1984.tb01831.x. PMID6725621.
36. ^Roth, BL; Driscol, J. 'PDSP K_i Database'. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
37. ^Berton JL, Seto M, Lindsley CW (June 2018). 'DARK Classics in Chemical Neuroscience: Phencyclidine (PCP)'. ACS Chem Neurosci. 9 (10): 2459–2474. doi:10.1021/acschemneuro.8b00266. PMID29953199.
38. ^ ^{abcdefghijklmnopqr}Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2013). 'The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor'. PLOS ONE. 8 (3): e59334. Bibcode:2013PLoSO..859334R. doi:10.1371/journal.pone.0059334. PMC3602154. PMID23527166.
39. ^ ^abcRothman RB (1994). 'PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site'. Neurotoxicol Teratol. 16 (4): 343–53. doi:10.1016/0892-0362(94)90022-1. PMID7968938.
40. ^Frohlich J, Van Horn JD (2014). 'Reviewing the ketamine model for schizophrenia'. J. Psychopharmacol. (Oxford). 28 (4): 287–302. doi:10.1177/0269881113512909. PMC4133098. PMID24257811.
41. ^Seeman P, Guan HC (2008). 'Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia'. Synapse. 62 (11): 819–28. doi:10.1002/syn.20561. PMID18720422.
42. ^ ^abKapur S, Seeman P (2002). 'NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia'. Mol. Psychiatry. 7 (8): 837–44. doi:10.1038/sj.mp.4001093. PMID12232776.
43. ^ ^abcSeeman P, Guan HC, Hirbec H (2009). 'Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil'. Synapse. 63 (8): 698–704. doi:10.1002/syn.20647. PMID19391150.
44. ^Rabin RA, Doat M, Winter JC (2000). 'Role of serotonergic 5-HT2A receptors in the psychotomimetic actions of phencyclidine'. Int. J. Neuropsychopharmacol. 3 (4): 333–338. doi:10.1017/S1461145700002091. PMID11343613.
45. ^ ^abcdGoodman CB, Thomas DN, Pert A, Emilien B, Cadet JL, Carroll FI, Blough BE, Mascarella SW, Rogawski MA, Subramaniam S (1994). 'RTI-4793-14, a new ligand with high affinity and selectivity for the (+)-MK801-insensitive [3H]1-]1-(2-thienyl)cyclohexyl]piperidine binding site (PCP site 2) of guinea pig brain'. Synapse. 16 (1): 59–65. doi:10.1002/syn.890160107. PMID8134901.
46. ^Large CH, Bison S, Sartori I, Read KD, Gozzi A, Quarta D, Antolini M, Hollands E, Gill CH, Gunthorpe MJ, Idris N, Neill JC, Alvaro GS (Jul 2011). 'The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: potential for novel treatments for schizophrenia'. The Journal of Pharmacology and Experimental Therapeutics. 338 (1): 100–13. doi:10.1124/jpet.110.178475. PMID21487071.
47. ^N. A. Anis, S. C. Berry, N. R. Burton & D. Lodge (1983). 'The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate'. British Journal of Pharmacology. 79 (2): 565–575. doi:10.1111/j.1476-5381.1983.tb11031.x. PMC2044888. PMID6317114.CS1 maint: Multiple names: authors list (link)
48. ^Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (Apr 2014). 'Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy'. Therapeutic Advances in Psychopharmacology. 4 (2): 75–99. doi:10.1177/2045125313507739. PMC3952483. PMID24688759.
49. ^Klockgether T, Turski L, Schwarz M, Sontag KH, Lehmann J (Oct 1988). 'Paradoxical convulsant action of a novel non-competitive N-methyl-D-aspartate (NMDA) antagonist, tiletamine'. Brain Research. 461 (2): 343–8. doi:10.1016/0006-8993(88)90265-X. PMID2846121.
50. ^Burns JM, Boyer EW (2013). 'Antitussives and substance abuse'. Substance Abuse and Rehabilitation. 4: 75–82. doi:10.2147/SAR.S36761. PMC3931656. PMID24648790.
51. ^Aguayo LG, Warnick JE, Maayani S, Glick SD, Weinstein H, Albuquerque EX (May 1982). 'Site of action of phencyclidine. IV. Interaction of phencyclidine and its analogues on ionic channels of the electrically excitable membrane and nicotinic receptor: implications for behavioral effects'. Molecular Pharmacology. 21 (3): 637–47. PMID6287200.
52. ^Zarantonello P, Bettini E, Paio A, Simoncelli C, Terreni S, Cardullo F (Apr 2011). 'Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists'. Bioorganic & Medicinal Chemistry Letters. 21 (7): 2059–63. doi:10.1016/j.bmcl.2011.02.009. PMID21334205.
53. ^Lin H, Vicini S, Hsu FC, Doshi S, Takano H, Coulter DA, Lynch DR (Sep 2010). 'Axonal α7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons'. Proceedings of the National Academy of Sciences of the United States of America. 107 (38): 16661–6. Bibcode:2010PNAS.10716661L. doi:10.1073/pnas.1007397107. PMC2944730. PMID20817852.
54. ^Fisher JL, Dani JA (Oct 2000). 'Nicotinic receptors on hippocampal cultures can increase synaptic glutamate currents while decreasing the NMDA-receptor component'. Neuropharmacology. 39 (13): 2756–69. doi:10.1016/s0028-3908(00)00102-7. PMID11044745.
55. ^Prestori F, Bonardi C, Mapelli L, Lombardo P, Goselink R, De Stefano ME, Gandolfi D, Mapelli J, Bertrand D, Schonewille M, De Zeeuw C, D'Angelo E (2013). 'Gating of long-term potentiation by nicotinic acetylcholine receptors at the cerebellum input stage'. PLOS ONE. 8 (5): e64828. Bibcode:2013PLoSO..864828P. doi:10.1371/journal.pone.0064828. PMC3669396. PMID23741401.
56. ^Seeman P, Ko F, Tallerico T (Sep 2005). 'Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics'. Molecular Psychiatry. 10 (9): 877–83. doi:10.1038/sj.mp.4001682. PMID15852061.
57. ^Giannini AJ, Nageotte C, Loiselle RH, Malone DA, Price WA (1984). 'Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity'. Journal of Toxicology. Clinical Toxicology. 22 (6): 573–9. doi:10.3109/15563658408992586. PMID6535849.
58. ^Rothman RB, Reid AA, Monn JA, Jacobson AE, Rice KC (Dec 1989). 'The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites'. Molecular Pharmacology. 36 (6): 887–96. PMID2557536.
59. ^Castellani S, Giannini AJ, Adams PM (1982). 'Effects of naloxone, metenkephalin, and morphine on phencyclidine-induced behavior in the rat'. Psychopharmacology. 78 (1): 76–80. doi:10.1007/BF00470593. PMID6815700.
60. ^ ^ab'Phencyclidine'. www.drugbank.ca. Retrieved 28 January 2019.
61. ^ ^abcBey, T; Patel, A (February 2007). 'Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug'. The California Journal of Emergency Medicine. 8 (1): 9–14. PMC2859735. PMID20440387.
62. ^Johnson, K M; Jones, S M (April 1990). 'Neuropharmacology of Phencyclidine: Basic Mechanisms and Therapeutic Potential'. Annual Review of Pharmacology and Toxicology. 30 (1): 707–750. doi:10.1146/annurev.pa.30.040190.003423. PMID2160793.
63. ^Olney JW, Labruyere J, Price MT (Jun 1989). 'Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs'. Science. 244 (4910): 1360–2. Bibcode:1989Sci..244.1360O. doi:10.1126/science.2660263. PMID2660263.
64. ^Hargreaves RJ, Hill RG, Iversen LL (1994). Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochirurgica. Supplementum. 60. pp. 15–9. doi:10.1007/978-3-7091-9334-1_4. ISBN978-3-7091-9336-5. PMID7976530.
65. ^Jansen, Karl. Ketamine: Dreams and Realities. MAPS, 2004. ISBN0-9660019-7-4
66. ^Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP (Mar 2005). 'Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain'. Schizophrenia Research. 73 (2–3): 147–52. doi:10.1016/j.schres.2004.02.003. PMID15653257.
67. ^Murray JB (May 2002). 'Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research'. The Journal of Psychology. 136 (3): 319–27. doi:10.1080/00223980209604159. PMID12206280.
68. ^Lodge, D; Mercier, M S (19 January 2017). 'Ketamine and phencyclidine: the good, the bad and the unexpected'. British Journal of Pharmacology. 172 (17): 4254–4276. doi:10.1111/bph.13222. ISSN0007-1188. PMC4556466. PMID26075331.
69. ^Javitt, Daniel C.; Zukin, Stephen R.; Heresco-Levy, Uriel; Umbricht, Daniel (19 January 2017). 'Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia'. Schizophrenia Bulletin. 38 (5): 958–966. doi:10.1093/schbul/sbs069. ISSN0586-7614. PMC3446214. PMID22987851.
70. ^Itzhak Y, Kalir A, Weissman BA, Cohen S (May 1981). 'New analgesic drugs derived from phencyclidine'. Journal of Medicinal Chemistry. 24 (5): 496–9. doi:10.1021/jm00137a004. PMID7241506.
71. ^Chaudieu I, Vignon J, Chicheportiche M, Kamenka JM, Trouiller G, Chicheportiche R (Mar 1989). 'Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs'. Pharmacology Biochemistry and Behavior. 32 (3): 699–705. doi:10.1016/0091-3057(89)90020-8. PMID2544905.
72. ^Development of PCP, 2006, CESAR (Center for Substance Abuse Research)
73. ^Zukin, Stephen R; Sloboda, Zili; Javitt, Daniel C (2005). 'Phencyclidine (PCP)'. In Lowinson, Joyce H; Ruiz, Pedro; Millman, Robert B; et al. (eds.). Substance Abuse: A Comprehensive Textbook (4th ed.). Philadelphia: Lippincott Williams & Wilkins. ISBN978-0-7817-3474-5. Retrieved 2 December 2010.
74. ^Maisto, Stephen A.; Mark Galizio; Gerard Joseph Connors (2004). Drug Use and Abuse. Thompson Wadsworth. ISBN978-0-15-508517-6.
75. ^US Drug Enforcement Administration March 12, 2014 Controlled Substances Page accessed June 15, 2014
76. ^US Drug Enforcement Administration August 30, 2013. Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Established Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014 Page Accessed June 15, 2014
77. ^'The Misuse of Drugs Act 1971 (Modification) Order 1979'. www.legislation.gov.uk. Retrieved 2016-01-31.

External links[edit]